Background-Oxidative stress is involved in the pathophysiology of atherosclerosis, diabetes mellitus, hypertension, obesity, and cigarette smoking, all of these being risk factors for coronary heart disease (CHD). We tested the hypothesis that risk factors of CHD are associated with abundant systemic oxidative stress. Methods and Results-We conducted a case-control study with 93 CHD patients and 93 control subjects frequencymatched by age and sex. Urinary excretion of the F 2 -isoprostane 8-iso-prostaglandin (PG) F 2␣ and its major urinary metabolite, 2,3-dinor-5,6-dihydro-8-iso-PGF 2␣ , were measured by gas chromatography-tandem mass spectrometry. Body mass index, systolic blood pressure, and C-reactive protein were elevated in CHD patients (PϽ0.01). Urinary 8-iso-PGF 2␣ and 2,3-dinor-5,6-dihydro-8-iso-PGF 2␣ also differed, from 77 (interquartile range, 61-101) to 139 (93-231) pmol/mmol creatinine and from 120 (91-151) to 193 (140 -275) pmol/mmol in control subjects and case subjects, respectively (PϽ0.001). 8-iso-PGF 2␣ and its metabolite were highly correlated (Spearman's ϭ0.664, PϽ0.001). HDL cholesterol was diminished in CHD patients (PϽ0.001). All of these characteristics predicted CHD in univariate analysis. In a multivariate model, the odds ratios were increased only for 8-iso-PGF 2␣ (Ն131 pmol/mmol, PϽ0.001) and C-reactive protein (Ͼ3 mg/L, PϽ0.01), ie, by 30.8 (95% CI, 7.7-124) and 7.2 (1.9 -27.6), respectively. 8-iso-PGF 2␣ was found to be a novel marker in addition to known risk factors of CHD, ie, diabetes mellitus, hypercholesterolemia, hypertension, and smoking. Urinary excretion of 8-iso-PGF 2␣ correlated with the number of risk factors for all subjects (PϽ0.001 for trend).
T he past decades have shown that oxidative stress is one fundamental of pathogenesis. This covers conditions as diverse as cancer, inflammation, neurodegenerative diseases, and aging. Likewise, oxidative damage is involved in the pathogenesis of atherosclerosis and cardiovascular disease. 1, 2 For many years, investigations in the field of oxidative stress were limited by a confusing number of surrogate markers with clinical relevance open to question. Reliable quantitative indices of free radical-induced modification of DNA, proteins, and lipids in vivo have emerged only recently. 3, 4 In the cardiovascular system, lipids are in the first line of radical attack. Morrow et al 5 have identified isoprostanes as end products of lipid peroxidation. Isoprostanes are chem-ically stable and can be measured noninvasively in human urine by mass spectrometry. A growing body of evidence has been provided by several groups underlining the validity of the isoprostanes as in vivo markers of oxidative stress. 3, 6, 7 Studies have suggested isoprostanes as markers for patients at risk of atherosclerosis and coronary heart disease (CHD): elevated isoprostane formation was found in underlying diseases such as diabetes mellitus, 8 hypertension and renovascular disease, 9 hyperlipidemia, 10 obesity, 11 and cigarette smoking. 12 The major risk factors for CHD are elevated blood pressure, elevated total cholesterol, LDL cholesterol, HDL cholesterol, diabetes mellitus, obesity, cigarette smoking, and advancing age. 13 Studies evaluating the quantitative relationships between these risks have elucidated their additive nature in predicting CHD. The relative magnitude at which markers of oxidative stress such as isoprostanes contribute to these risk factors is as yet unknown. In addition, the extent to which oxidative stress contributes independently to hypertension, diabetes mellitus, hyperlipidemia, and obesity is open to question. Finally, increasing oxidative stress from different clinical conditions would be expected to contribute to CHD in a cumulative manner.
To evaluate the hypothesis that isoprostanes are independent and cumulative risk markers of CHD, we conducted a case-control study. Ninety-three patients with a confirmed diagnosis of CHD were included and frequency-matched by age and sex with control subjects (controls) from the general population. The isoprostanes 8-iso-prostaglandin (PG) F 2␣ and 2,3-dinor-5,6-dihydro-8-iso-PGF 2␣ were measured by gas chromatography-tandem mass spectrometry (GC-tandem MS) along with C-reactive protein (CRP), oxidized LDL, and further biochemical parameters.
Methods

Patients and Study Protocol
Patients between 35 and 80 years old with established coronary artery disease were recruited for this study. Patients were included if they had stable angina pectoris or a history of myocardial infarction, plus diagnostic criteria for recurrent myocardial ischemia (positive exercise ECG, evidence for myocardial ischemia in thallium scintigraphy, documentation of coronary stenosis by coronary angiography). Age-and sex-matched healthy controls were recruited from the general population via local newspaper advertisement. They were included in the study if they had no clinical or diagnostic evidence for coronary artery disease. Patients or controls suffering from any concomitant acute or chronic severe disease, from renal failure (creatinine clearance Ͻ30 mL/min) or hepatic insufficiency, severe chronic heart failure (NYHA functional class III or above), acute occlusive cardiovascular events (ie, within the previous 30 days before inclusion into the study), or Ͼ80 years old were excluded from the study. We assessed eligibility, obtained informed consent, and included 93 patients and 93 controls in the study. The study protocol was approved by the local Institutional Review Board for Studies in Humans.
All patients and controls were invited to the study center in the morning. The patients were asked for their previous medical history and the presence of cardiovascular risk factors by use of a standardized questionnaire. A fasting blood sample was drawn, and a urine sample was collected into a vial containing 5 mmol/L 4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (4-hydroxy-TEMPO) and 5 mmol/L EDTA as antioxidants. Blood samples were centrifuged (2000g, 10 minutes, 4°C), and plasma was divided into aliquots and stored at Ϫ20°C until analysis. Urine samples were divided into aliquots and kept frozen at Ϫ80°C until analysis. Diurnal variation of creatinine-indexed isoprostane excretion was assessed in 3 subjects. No divergence was found between morning urine samples and 24-hour urine samples. 14 Therefore, we decided to collect morning urine samples instead of 24-hour collection.
Biochemical Analyses
Urinary concentrations of 8-iso-PGF 2␣ and 2,3-dinor-5,6-dihydro-8iso-PGF 2␣ were determined by GC-tandem MS as described previously in detail. 15 Briefly, urine samples were thawed, and labeled internal standards of 8-iso-PGF 2␣ and 2,3-dinor-5,6-dihydro-8-iso-PGF 2␣ were added at 1 ng/mL, solid-phase-extracted on ODS, and subjected to thin-layer chromatography on silica gel. Transitions from m/z 569 to m/z 299 and from m/z 543 to m/z 273 were monitored for 8-iso-PGF 2␣ and 2,3-dinor-5,6-dihydro-8-iso-PGF 2␣ , respectively, by GC-tandem MS. Validity of the method was proven as reported previously. 16 Urinary concentrations of 8-iso-PGF 2␣ and 2,3-dinor-5,6-dihydro-8-iso-PGF 2␣ were corrected by urinary creatinine concentration to account for differences in renal excretory function. Plasma concentration of oxidized LDL cholesterol was determined with a commercially available immunoassay (Mercodia SA). Plasma concentration of CRP was measured by a highsensitivity assay (N Latex Mono test) on a Behring BN II nephelometer with polystyrene microbeads coated with monoclonal mouse antibodies. 17 The detection limit of the assay was 0.2 mg/L. Plasma total cholesterol, LDL and HDL cholesterol, and triglyceride levels as well as plasma and urinary creatinine concentrations were determined by standard laboratory methods using certified assays in the local clinical laboratory.
Calculations and Statistical Methods
All data were tested for normal distribution with the Kolmogorov-Smirnov test. The distribution of 8-iso-PGF 2␣ , 2,3-dinor-5,6-dihydro-8-iso-PGF 2␣ , and CRP was highly skewed, as reported previously. 18, 19 Continuous variables were expressed as arithmetic meanϮSD if normally distributed or otherwise by median with 25% and 75% percentiles. Because explorative data analysis was performed, no correction of the type I error was made. Differences between groups are given as mean or median differences. The 95% CIs are given for mean or median differences. Comparisons between 2 subgroups were performed with the Mann-Whitney U test (2-sided). Bivariate correlations were analyzed by Spearman's as indicated. Continuous variables were split into tertiles for univariate and multivariate analysis. Categorized biochemical characteristics (body mass index, systolic blood pressure, CRP, HDL cholesterol, and 8-iso-PGF 2␣ ) and risk factors of CHD (diabetes mellitus, hypercholesterolemia, hypertension, and cigarette smoking) were included into the unconditional logistic regression models. Biochemical characteristics were included stepwise in one multivariate model and risk factors of CHD, including 8-iso-PGF 2␣ , in a second multivariate model. Estimates of risk (odds ratios) and 95% CI were calculated on the basis of coefficients from the logistic regression models. For statistical analyses, SPSS version 11.0 was used.
Results
We enrolled 93 CHD patients and 93 controls, frequencymatched by sex and age. Characteristics of patients and controls are given in Table 1 . Total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels were lower in patients than in controls. Systolic blood pressure and body mass index were higher in the CHD group. Oxidative stress and inflammation were evaluated by oxidized LDL, isoprostanes, and high-sensitive CRP, respectively. CRP was more abundant in patients. Oxidized LDL was not different in patients and controls. The prevalence of cardiovascular risk factors for both groups is given in Table 2 . As expected, patients were more likely to have diabetes mellitus, hypercholesterolemia, or hypertension. Patients were also more often smokers. Likewise, lipid-lowering agents (64% versus 6%, patients and controls, respectively), ␤-blockers (61% versus 6%), ACE inhibitors (47% versus 3%), calcium antagonists (17% versus 6%), nitrates (62% versus 1%), and aspirin (100% versus 4%) were used more frequently in patients.
Urinary excretion of 8-iso-PGF 2␣ was 139 (93-231) pmol/mmol creatinine in patients and 77 (61-101) pmol/ mmol creatinine in controls (PϽ0.001, Figure 1 ). Excretion of 8-iso-PGF 2␣ metabolite was 193 (140 -275) pmol/mmol creatinine in patients and 120 (91-151) pmol/mmol creatinine in controls (PϽ0.001). Individual urinary excretion of the metabolite was highly dependent on 8-iso-PGF 2␣ excretion (ϭ0.664, PϽ0.001). Neither 8-iso-PGF 2␣ nor its metabolite correlated with blood pressure, total cholesterol, LDL cholesterol, or HDL cholesterol. Treatment with lipid-lowering agents, ␤-blockers, ACE inhibitors, calcium antagonists, and nitrates was not associated with reduced urinary excretion of 8-iso-PGF 2␣ or its metabolite in patients. There was no correlation between the 2 isoprostanes and oxidized LDL. However, a correlation was found between 8-iso-PGF 2␣ , 2,3-dinor-5,6-dihydro-8-iso-PGF 2␣ , and CRP (ϭ0.225, PϽ0.01, and ϭ0.321, PϽ0.001, respectively). Urinary excretion of 8-iso-PGF 2␣ correlated with the number of cardiovascular risk factors in the 2 groups (PϽ0.001 for trend, Figure 2 ).
On univariate analysis, tertiles of body mass index, systolic blood pressure, CRP, and 8-iso-PGF 2␣ were concentrationdependent risk markers of CHD ( Table 2 ). The odds ratio for HDL cholesterol was decreased for plasma levels Ͼ0.9 mmol/L. Diabetes mellitus, hypercholesterolemia, hypertension, cigarette smoking, and obesity (body mass index Ͼ30 kg/m 2 ) predicted CHD in univariate analysis as well.
On multivariate analysis, the categorized characteristics of patients, including body mass index (Ͼ30 kg/m 2 ), systolic blood pressure, CRP, HDL cholesterol, and 8-iso-PGF 2␣ , were tested as independent markers of CHD (Table 3 ). Only urinary excretion of 8-iso-PGF 2␣ remained a strong risk marker in the 2 higher tertiles. The odds ratios were increased by 4.61 for 8-iso-PGF 2␣ levels Ͼ80 pmol/mmol creatinine and by 30.8 for 8-iso-PGF 2␣ levels Ͼ130 pmol/mmol creatinine. For CRP, an increased risk was found only for the highest tertile, ie, by 7.20 for CRP Ͼ3.0 mg/L. In a second model of multivariate analysis, tertiles of 8-iso-PGF 2␣ were included together with risk factors of CHD (Table 4 ). Included risk factors were diabetes mellitus, hypercholesterolemia, hypertension, and cigarette smoking. With the exception of cigarette smoking, all other risk factors remained strong and independent predictors of CHD. 8-iso-PGF 2␣ was found to be a strong concentration-dependent risk marker in this logistic regression model also.
Discussion
Cardiovascular risk is believed to be at least in part related to increased systemic oxidative stress. Established risk factors of CHD have been associated with elevated levels of markers of systemic oxidative stress such as isoprostanes. 8 -12 However, such evidence is restricted to single risk factors. The principal result of our study is that systemic oxidative stress, evaluated as creatinine-indexed urinary isoprostanes, is related to the number of cardiovascular risk factors as well as to the prevalence of CHD. Other categorized patients characteristics, such as body mass index, systolic blood pressure, HDL cholesterol, and CRP, included in univariate analysis also predicted the prevalence of CHD (Table 2 ). However, in multivariate analysis, only isoprostane and CRP remained independent risk markers of CHD. Cigarette smoking, hypertension, hypercholesterolemia, diabetes mellitus, and obesity are well-known risk factors of CHD. 13 With the exception of obesity, they also predicted the prevalence of CHD in our study. Obesity missed the significance level probably because of its comparatively low prevalence and was therefore not included into the multivariate analysis. Included risk factors, ie, diabetes mellitus, arterial hypertension, and hypercholesterolemia remained strong predictors of CHD in multivariate regression analysis. 8-iso-PGF 2␣ divided into tertiles was found to be a strong predictor of CHD in this model as well. The odds ratio was significantly elevated for levels of 8-iso-PGF 2␣ Ͼ80 pmol/mmol creatinine. The close relationship previously observed between cigarette smoking and increased lipid peroxidation may explain why cigarette smoking was not found to be an independent risk marker in multivariate analysis. 12 However, our results confirm previous studies showing increased isoprostane formation in diabetes mellitus, renal hypertension, hypercholesterolemia, and cigarette smoking. 8 -10,12 Furthermore, they are in line with recent findings from the Framingham study showing an association between urinary excretion of 8-iso-PGF 2␣ and history of cardiovascular disease, smoking, and body mass index. 18 Moreover, our data show for the first time that systemic oxidative stress is an additive risk marker of CHD in addition to traditional risk factors (Table 4 ). In line with this result, urinary excretion of 8-iso-PGF 2␣ continuously increased with the number of traditional CHD risk factors (Figure 2) . To confirm the validity of our data, we correlated 8-iso-PGF 2␣ with its major urinary metabolite, 2,3-dinor-5,6dihydro-8-iso-PGF 2␣ . We found a very good correlation (Spearman's ϭ0.66) analyzing both parameters with GCtandem MS. Both were highly different between case subjects (cases) and controls (PϽ0.001). Further evidence for the suitability of 8-iso-PGF 2␣ as a novel risk marker comes from analysis of possible confounders. Not surprisingly, in our cohort of cases, we found decreased levels of total cholesterol, LDL cholesterol, and triglycerides, reflecting the widespread use of lipid-lowering therapy in CHD patients (64%). Urinary excretion of 8-iso-PGF 2␣ and its metabolite were not confounded by either lipid-lowering therapy or by total cholesterol, LDL cholesterol, or triglyceride levels. This finding is of particular interest, because it has been demonstrated that intervention with statins in mildly hypercholesterolemic patients reduced oxidant burden, ie, 8-iso-PGF 2␣ and 3-nitrotyrosine formation. 20, 21 However, our trial was designed as a case-control study and therefore was not intended to detect such effects. Recently, a difference in urinary 8-iso-PGF 2␣ in CHD patients with 1-vessel and multivessel disease was found. 22 Unfortunately, we were not able to confirm this observation in our study (data not shown).
Interestingly, a correlation between 8-iso-PGF 2␣ , its metabolite, and CRP existed (ϭ0.23 and ϭ0.32, respectively; PϽ0.01). This observation may result in part from the involvement of inflammatory and oxidative processes in atherosclerosis. 1, 23, 24 Moderately elevated CRP is associated with a high risk of coronary events, possibly because of inflammation of the vascular bed. 25 Although inflammation works hand in hand with oxidative modifications, oxidative stress may occur independently of inflammation. In support of this, we found 8-iso-PGF 2␣ and high-sensitive CRP to be independent predictors of CHD (Table 3) . Thus, the evaluation of both 8-iso-PGF 2␣ and CRP should be superior to the measurement of either parameter alone. Another parameter of lipid peroxidation, oxidized LDL, failed to show a difference in our case-control design. There is substantial evidence that oxidized LDL is present in vivo within atherosclerotic blood vessels. 26, 27 Probably, circulating oxidized LDL derives, at least in part, from rupture of atherosclerotic plaques. Thus, elevated levels of oxidized LDL showed a positive correlation with the severity of acute coronary events. 28 Because acute coronary syndrome and related conditions were excluded in our study, this could explain the similar levels of oxidized LDL in both groups. Interestingly, Cipollone et al 29 previously reported highly elevated urinary 8-iso-PGF 2␣ measured in patients with unstable angina, supporting the important role of oxidative stress in a worse scenario than investigated in our study.
In conclusion, our findings introduce 8-iso-PGF 2␣ as a new risk marker in the field of cardiovascular disease. 8-iso-PGF 2␣ was identified as an independent and cumulative risk marker of CHD together with diabetes mellitus, arterial hypertension, hypercholesterolemia, and elevated CRP. The case-control design used in our study does not allow us to show the value of 8-iso-PGF 2␣ for predicting future coronary events. Therefore, we initiated a cohort study to evaluate 8-iso-PGF 2␣ as a risk factor for coronary events.
